February 18, 2025

FDA Clears Aptima SARS-CoV-2 Assay for High-Throughput Testing

FDA grants 510(k) clearance for Hologic’s Aptima SARS-CoV-2 assay, which uses the Panther system for high-throughput RNA detection.

Conexiant

February 17, 2025

FDA Approves GSK’s 5-in-1 MenABCWY Vaccine

FDA approves GSK’s Penmenvy, a 5-in-1 meningococcal vaccine for adolescents and young adults, targeting five major serogroups of Neisseria meningitidis that cause invasive meningococcal disease.

Conexiant

February 17, 2025

Skin Metabolism and Exudation Limit Tattoo Ink Absorption, Study Finds

Researchers examined systemic absorption, metabolism, and excretion of tattoo ink tracers, providing evidence for a cutaneous first-pass effect and measuring systemic exposure levels.

Conexiant

February 17, 2025

FDA Approves GSK’s 5-in-1 MenABCWY Vaccine

FDA approves GSK’s Penmenvy, a 5-in-1 meningococcal vaccine for adolescents and young adults, targeting five major serogroups of Neisseria meningitidis that cause invasive meningococcal disease.

Conexiant

February 14, 2025

Study: Patients Trust Female Docs Less

Study findings and an interview with the lead investigator.

Conexiant

February 12, 2025

Immunosuppressive Therapy Withdrawal and Renal Relapse Risks

Study finds prolonged immunosuppressive therapy duration and gradual tapering reduce renal relapse risk in proliferative lupus nephritis.

Conexiant

February 12, 2025

Fluoroquinolones vs Amoxicillin: Anaphylaxis Risk

Moxifloxacin carries the highest anaphylaxis risk among fluoroquinolones, while the entire drug class shows a lower risk than amoxicillin, Penn State researchers reported.

Conexiant

February 12, 2025

New Tests Reshape Food Allergy Diagnosis Landscape

A comprehensive review published in JACI reveals how emerging diagnostic tools like the basophil activation test could reduce reliance on oral food challenges while improving accuracy for the 10% of people affected by food allergies.

Conexiant

February 11, 2025

Skin Manifestations of COVID: IFN-1 Link Found

Pseudochilblains were linked to exaggerated IFN-1 production by plasmacytoid dendritic cells, according to new findings on COVID-19-related skin diseases.

Conexiant